Literature DB >> 19080754

Two strikes against mycophenolate mofetil therapy for myasthenia gravis.

Michio Hirano.   

Abstract

Entities:  

Year:  2009        PMID： 19080754     DOI： 10.1007/s11910-009-0009-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  6 in total

Review 1.  The epidemiology of myasthenia gravis.

Authors:  Lawrence H Phillips
Journal:  Semin Neurol       Date:  2004-03       Impact factor: 3.420

2.  Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.

Authors:  R A Hauser; A R Malek; R Rosen
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

3.  Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.

Authors:  E Ciafaloni; J M Massey; B Tucker-Lipscomb; D B Sanders
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

4.  Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.

Authors:  V Chaudhry; D R Cornblath; J W Griffin; R O'Brien; D B Drachman
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

5.  Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.

Authors:  Matthew N Meriggioli; Julie Rowin; Judith G Richman; Sue Leurgans
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

6.  Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.

Authors:  M N Meriggioli; E Ciafaloni; K A Al-Hayk; J Rowin; B Tucker-Lipscomb; J M Massey; D B Sanders
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.